TSI Pharmaceuticals Acquires National ProPackTSI Pharmaceuticals Acquires National ProPack
June 6, 2013
The acquisition includes ProPacks manufacturing facility in Brisbane, which will allow TSI to manufacture liquids and creams in topical format for therapeutic products and industrial applications in a wide variety of jars, tubes and bottles.
According to Ian Chant, TSI Pharmaceuticals managing director, the acquisition will strengthen TSI Pharmaceuticals' product offerings, particularly related to the production of its locally made liquids and creams. Both National ProPack and TSI Pharmaceuticals are backed by the TSI Group, a global researcher, developer and manufacturer of ingredients and finished products with offices in Europe, Japan, China, Australia and the United States.
As part of the TSI Group, ProPack will gain access to worldwide innovation, economic purchasing and the vertical integration of closely controlled raw material manufacturers.
Last year, TSI acquired contract manufacturer Yessamin Health Company, a Norwegian-invested facility in China.
You May Also Like
Sep 28, 2023
Unlocking vitality: The power of mineral-enriched gummies – articleSep 27, 2023
Innovation in stress and sleep management: Holixer™– white paperSep 22, 2023
Probi study finds subjects’ brains worked better under stress with probioticSep 29, 2023
Cognitive health growth comes out on top: A range of solutions for diverse needs continue to emerge and win – product development guideSep 25, 2023